VitaDAO, a decentralized autonomous organization dedicated to funding and advancing early-stage longevity research, has launched its first biotech firm Matrix Biosciences.

The launch follows a near-unanimous community vote earlier this year approving a collaboration with the University of Rochester’s Aging Research Center co-chair Dr. Vera Gorbunova.

An initial tranche of $300,000 from VitaDAO will be made available to Matrix Bio, followed by additional funding through IP-NFT fractionalization in early 2024 — non-fungible tokens intended to represent intellectual property.

IP-NFT fractionalization relies on technology from the VitaDAO-associated platform Molecule, allowing researchers to list NFT projects on its marketplace. The additional funding target from IP-NFTs will be determined …